Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med 2023;389:504-13 CONCLUSIONS: In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone

Presenta: Dr. Francisco Osses

22 de mayo 2024 16:00hrs / 17:15hrs

Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms A Retrospective Cohort Study. DOI: Extended anaerobic coverage likely is unnecessary in aspiration pneumonia because it is associated with no additional mortality benefit, only an increased risk of C. difficile colitis.

Presenta: Dra. Macarena Lagos

15 de mayo 2024 16:00hrs / 17:15hrs

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer. N Engl J Med 2023; 388:489-498. In patients with peripheral NSCLC with a tumor size of 2 cm or less and pathologically confirmed node-negative disease in the hilar and mediastinal lymph nodes, sublobar resection was not inferior to lobectomy with respect to disease-free survival. Overall survival was similar with the two procedures.

Presenta: Dr. Jorge Verdugo

08 de mayo 2024 16:00hrs / 17:15hrs

Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe Asthma. Thorax 2023;78:868–874. Conclusion A treatment algorithm to adjust OCS using blood eosinophil count and FeNO is feasible in a clinical setting and resulted in a reduced odds of an ED visit. This warrants further study to optimise the use of OCS in the future

Presenta: Dr. Francisco Osses

24 de abril 2024 16:00hrs / 17:15hrs

Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. N Engl J Med 2022;386:2071-83. CONCLUSIONS: The risk of severe asthma exacerbation was significantly lower with as-needed use of a fixed-dose combination of 180 ?g of albuterol and 160 ?g of budesonide than with as-needed use of albuterol alone among patients with uncontrolled moderate to-severe asthma who were receiving a wide range of inhaled glucocorticoid-containing maintenance therapies.

Presenta: Dr. Felipe Rozas

15 de abril 2024 16:00hrs / 17:15hrs